Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau

  title={Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau},
  author={John Hardy and Karen E. Duff and Katrina Gwinn Hardy and Jordi P{\'e}rez-Tur and Michael L. Hutton},
  journal={Nature Neuroscience},
Molecular genetic analysis is revealing the etiologies of Alzheimer's disease (AD) and related dementias. Here we review genetic and molecular biological evidence suggesting that the peptide Aβ42 is central to the etiology of AD. Recent data also suggests that dysfunction in the cytoskeletal protein tau is on the pathway that leads to neurodegeneration and dementia. Tau is produced either indirectly, by Aβ42, or directly, in some forms of frontotemporal dementia by mutations in tau itself… 
Tau protein as a therapeutic target in Alzheimer's disease and other neurodegenerative disorders
The microtubule associated protein tau is the key component of the neurofibrillary pathology seen in Alzheimer’s disease and other rare causes of dementia and the discovery of tau gene mutations as a rare cause of neurodegenerative disease has added impetus to research in this area.
Frontotemporal Lobar Degeneration(FTLD) and Molecular Genetics of Tau Protein
The findings first that the degree of dementia does not correlate with the number of plaques and second that the neurofibrillary tangle formation seems to predate plaque formation suggest the independent importance of tau abnormality in AD research which is involved in the neuroFibrillaryTangle formation.
Genetics of Alzheimer’s Disease and Related Disorders
The theme of this chapter is that genetic analysis—together with pathology investigation—has shown that these diseases share common mechanisms of neurodegeneration, and that they can be grouped into one broadly sketched pathway of pathogenesis.
Pathophysiology of Alzheimer's disease.
A review of genome mutation and Alzheimer's disease.
A biologically plausible chromosome instability model is proposed to explain some of the features of the disease andome damage biomarkers such as aneuploidy of chromosome 17 and 21, oxidative damage to DNA and telomere shortening together with abnormal expression of APP, beta amyloid and tau proteins are discussed in terms of their potential value as risk biomarkers.
REVIEW: tau protein pathology in Alzheimer’s disease and related disorders
  • Tolnay, Probst
  • Biology
    Neuropathology and applied neurobiology
  • 1999
This review outlines the morphological and biochemical features of some major tauopathies, e.g. Alzheimer’s disease, argyrophilic grain disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration, and suggests a new understanding of neurodegenerative disorders characterized by filamentous nerve cell inclusions.
Role of Amyloid-β and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid Cascade.
A novel view of AD pathogenesis is proposed in which extracellular oligomers of Aβ and tau act in parallel and upstream of A βPP, paving the way to an increased interest toward AβPP, both for understanding the pathogenesis of the disease and elaborating new therapeutic strategies.
Neurofibrillary tangle parkinsonian disorders—tau pathology and tau genetics
The recent description of mutation in tau in frontotemporal dementia, and a common variant of tau that predisposes to PSP, and the relationship of these changes to the tau protein subgroups offers new insights into the pathogenesis of these disorders.
The genetics of disorders with synuclein pathology and parkinsonism.
Genetic analysis of the synuclein diseases and the tau diseases may indicate that thissynuclein pathway is an alternative to the t Tau pathway to cell death.


Amyloid deposition as the central event in the aetiology of Alzheimer's disease.
Age, neurofibrillary changes, Aβ-amyloid and the onset of Alzheimer's disease
Amyloid, the presenilins and Alzheimer's disease
  • J. Hardy
  • Biology
    Trends in Neurosciences
  • 1997
Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17: A New Group of Tauopathies
The clinical and neuropathological features of the disease in these families suggest that Frontotemporal Dementia and Parkinsonism linked to chromosome 17 is a distinct disorder, with the presence of abundant tau deposits defining this disorder as a new tauopathy.
Amyloid β-Protein and the Genetics of Alzheimer's Disease*
  • D. Selkoe
  • Biology, Chemistry
    The Journal of Biological Chemistry
  • 1996
The effort to decipher the mechanism of Alzheimer's disease has attracted the interest of investigators from diverse biological disciplines, including biochemistry, cell biology, molecular genetics, neuroscience, and structural biology, and it is increasingly likely that AD will become a premier example of the successful application of biological chemistry to the identification of rational therapeutic targets in a major human disease.
The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis.
  • R. Terry
  • Biology
    Journal of neuropathology and experimental neurology
  • 1996
This paper attempts to put together in the form of a flow sheet (Fig. 1) the several known alterations, both chemical and structural, of brain tissue in Alzheimer disease, which ultimately result in
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia.
The results show that dysregulation of tau protein production can cause neurodegeneration and imply that the FTDP-17 gene is the tau gene, which has major implications for Alzheimer's disease and other tauopathies.
Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production
C cultured cells which express a β-APP complementary DNA bearing a double mutation found in a Swedish FAD family produce ∼6–8-fold more Aβ than cells expressing normalβ-APP, and this increase is confirmed for elucidating the fundamental mechanism of Alzheimer's disease.
A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1
A novel variant of Alzheimer's disease in a Finnish pedigree with 17 affected individuals of both sexes in three generations caused by a deletion of exon 9 (Δ9) of the presenilin 1 (PSI) gene from the mRNA was described.
A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia
The results suggest that homozygosity of a common variant (−491 A) is associated with increased risk for AD, and that this association is independent of APOEs4 status.